摘要
Abstract
Objective To analyze the effects of adding thalidomide to the VAD regimen(vincristine,doxorubicin,and dexa-methasone)in the treatment of patients with multiple myeloma(MM).Methods Seventy MM patients admitted to our hospital between March 2023 and March 2024 were randomly selected for a controlled trial.They were assigned to two groups:the control group(n=35),treated with the VAD regimen,and the observation group(n=35),treated with tha-lidomide combined with the VAD regimen.The therapeutic efficacy between the two groups was compared.Results Before treatment,there were no significant differences between the two groups in erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),β2-microglobulin(β2-MG),and M-protein levels(P>0.05).After treatment,the observation group showed significantly lower levels of these laboratory indicators compared to the control group(P<0.05).The overall re-sponse rate in the observation group was significantly higher than that in the control group(P<0.05).The difference in in-cidence of adverse reactions between the observation group and the control group was not significant(P>0.05).Conclusion The combination of thalidomide with the VAD regimen significantly improves the therapeutic efficacy in patients with MM,effectively ameliorates the patient's physical condition,and has a high safety profile.This combination therapy war-rants clinical promotion.关键词
沙利度胺/VAD方案/多发性骨髓瘤/临床效果Key words
Thalidomide/VAD regimen/Multiple myeloma/Therapeutic efficacy分类
医药卫生
